Stay updated with breaking news from Doublet Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer
Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
David R. Wise, MD, PhD, discusses changes in the optimal use of intensified treatment regimens in patients with metastatic hormone-sensitive prostate cancer.
Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.
Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.